JOENJA

JOENJA is indicated for the treatment of activated phosphoinositide 3 kinase delta syndrome (APDS) in adults and adolescents 12 years of age and older and weighing 45 kg or more.

• Composition: Leniolisib (as phosphate)70 mg
• Method of administration: Tablets, for oral use
• Manufacturer: Pharming Technologies B.V.